Bildkälla: Stockfoto

Egetis Therapeutics: New Data Validate the Long-term Efficacy of Emcitate - Redeye

Redeye comments on the newly published data from long-term treatment of lead candidate Emcitate (tiratricol) in MCT8 deficiency patients. We believe that the data demonstrate the importance of Emcitate and reaffirm our strong view of the treatment.

Redeye comments on the newly published data from long-term treatment of lead candidate Emcitate (tiratricol) in MCT8 deficiency patients. We believe that the data demonstrate the importance of Emcitate and reaffirm our strong view of the treatment.
Börsvärldens nyhetsbrev
ANNONSER